Changes and regulation of the c5a receptor on neutrophils during septic shock in humans

Journal of Immunology

Volumn 190, Issue 8, 2013, Pages 4215-4225

  Unnewehr, Heike ^a   Rittirsch, Daniel ^a   Sarma, J Vidya ^b   Zetoune, Firas ^b   Flierl, Michael A ^a   Perl, Mario ^a   Denk, Stephanie ^a   Weiss, Manfred ^a   Schneider, Marion E ^a   Monk, Peter N ^c   Neff, Thomas ^b   Mihlan, Michael ^d   Barth, Holger ^e   Gebhard, Florian ^a   Ward, Peter A ^b   Huber Lang, Markus ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d HANS KNÖLL INSTITUTE   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5B; HYDROGEN PEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CELL STRUCTURE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DEPOLYMERIZATION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INNATE IMMUNITY; INTERNALIZATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESPIRATORY BURST; SEPTIC SHOCK; SUPERNATANT; SURVIVAL RATE;

ADULT; AGED; ANIMALS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, COMPLEMENT; SHOCK, SEPTIC; SURVIVAL;

EID: 84875994477     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200534     Document Type: Article

References (61)

1. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29: 1303-1310.
2. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554.
3. Guidet, B., P. Aegerter, R. Gauzit, P. Meshaka, and D. Dreyfuss; CUB-Réa Study Group. 2005. Incidence and impact of organ dysfunctions associated with sepsis. Chest 127: 942-951.
4. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891.
5. Hotchkiss, R. S., and I. E. Karl. 2003. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348: 138-150.
6. Boomer, J. S., K. To, K. C. Chang, O. Takasu, D. F. Osborne, A. H. Walton, T. L. Bricker, S. D. Jarman, II, D. Kreisel, A. S. Krupnick, et al. 2011. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306: 2594-2605.
7. Hotchkiss, R. S., P. E. Swanson, B. D. Freeman, K. W. Tinsley, J. P. Cobb, G. M. Matuschak, T. G. Buchman, and I. E. Karl. 1999. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit. Care Med. 27: 1230-1251.
8. Hotchkiss, R. S., K. W. Tinsley, P. E. Swanson, K. C. Chang, J. P. Cobb, T. G. Buchman, S. J. Korsmeyer, and I. E. Karl. 1999. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA 96: 14541-14546.
9. Oberholzer, C., A. Oberholzer, F. R. Bahjat, R. M. Minter, C. L. Tannahill, A. Abouhamze, D. LaFace, B. Hutchins, M. J. Clare-Salzler, and L. L. Moldawer. 2001. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc. Natl. Acad. Sci. USA 98: 11503-11508.
10. Botha, A. J., F. A. Moore, E. E. Moore, B. Fontes, A. Banerjee, and V. M. Peterson. 1995. Postinjury neutrophil priming and activation states: therapeutic challenges. Shock 3: 157-166.
11. Huber-Lang, M. S., E. M. Younkin, J. V. Sarma, S. R. McGuire, K. T. Lu, R. F. Guo, V. A. Padgaonkar, J. T. Curnutte, R. Erickson, and P. A. Ward. 2002. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169: 3223-3231.
12. Levy, M. M., M. P. Fink, J. C. Marshall, E. Abraham, D. Angus, D. Cook, J. Cohen, S. M. Opal, J. L. Vincent, and G. Ramsay; SCCM/ESICM/ACCP/ATS/SIS. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31: 1250-1256.
13. Zhang, Q., M. Raoof, Y. Chen, Y. Sumi, T. Sursal, W. Junger, K. Brohi, K. Itagaki, and C. J. Hauser. 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104-107.
14. Brealey, D., M. Brand, I. Hargreaves, S. Heales, J. Land, R. Smolenski, N. A. Davies, C. E. Cooper, and M. Singer. 2002. Association between mito-chondrial dysfunction and severity and outcome of septic shock. Lancet 360: 219-223.
15. Tracey, K. J. 2002. The inflammatory reflex. Nature 420: 853-859.
16. Ward, P. A. 2004. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4: 133-142.
17. Czermak, B. J., V. Sarma, C. L. Pierson, R. L. Warner, M. Huber-Lang, N. M. Bless, H. Schmal, H. P. Friedl, and P. A. Ward. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5: 788-792.
18. Gerard, N. P., and C. Gerard. 1991. The chemotactic receptor for human C5a anaphylatoxin. Nature 349: 614-617.
19. Huber-Lang, M. S., N. C. Riedeman, J. V. Sarma, E. M. Younkin, S. R. McGuire, I. J. Laudes, K. T. Lu, R. F. Guo, T. A. Neff, V. A. Padgaonkar, et al. 2002. Protection of innate immunity by C5aR antagonist in septic mice. FASEB J. 16: 1567-1574.
20. Guo, R. F., N. C. Riedemann, and P. A. Ward. 2004. Role of C5a-C5aR interaction in sepsis. Shock 21: 1-7.
21. Rittirsch, D., M. A. Flierl, B. A. Nadeau, D. E. Day, M. Huber-Lang, C. R. Mackay, F. S. Zetoune, N. P. Gerard, K. Cianflone, J. Köhl, et al. 2008. Functional roles for C5a receptors in sepsis. Nat. Med. 14: 551-557.
22. Huber-Lang, M., V. J. Sarma, K. T. Lu, S. R. McGuire, V. A. Padgaonkar, R. F. Guo, E. M. Younkin, R. G. Kunkel, J. Ding, R. Erickson, et al. 2001. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166: 1193-1199.
23. Gerard, C. 2003. Complement C5a in the sepsis syndrome - too much of a good thing? N. Engl. J. Med. 348: 167-169.
24. Ward, P. A. 2010. The harmful role of c5a on innate immunity in sepsis. J. Innate Immun. 2: 439-445.
25. Guo, R. F., N. C. Riedemann, K. D. Bernacki, V. J. Sarma, I. J. Laudes, J. S. Reuben, E. M. Younkin, T. A. Neff, J. D. Paulauskis, F. S. Zetoune, and P. A. Ward. 2003. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J. 17: 1889-1891.
26. Solomkin, J. S., M. K. Jenkins, R. D. Nelson, D. Chenoweth, and R. L. Simmons. 1981. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation. Surgery 90: 319-327.
27. Furebring, M., L. D. Håkansson, P. Venge, B. Nilsson, and J. Sjölin. 2002. Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis. Crit. Care 6: 363-370.
28. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus, R. M. Schein, and W. J. Sibbald; The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655.
29. Mihlan, M., A. M. Blom, K. Kupreishvili, N. Lauer, K. Stelzner, F. Bergström, H. W. Niessen, and P. F. Zipfel. 2011. Monomeric C-reactive protein modulates classic complement activation on necrotic cells. FASEB J. 25: 4198-4210.
30. Potempa, L. A., J. N. Siegel, B. A. Fiedel, R. T. Potempa, and H. Gewurz. 1987. Expression, detection and assay of a neoantigen (Neo-CRP) associated with a free, human C-reactive protein subunit. Mol. Immunol. 24: 531-541.
31. Stöve, S., T. Welte, T. O. Wagner, A. Kola, A. Klos, W. Bautsch, and J. Köhl. 1996. Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome. Clin. Diagn. Lab. Immunol. 3: 175-183.
32. Nakae, H., S. Endo, K. Inada, and M. Yoshida. 1996. Chronological changes in the complement system in sepsis. Surg. Today 26: 225-229.
33. Takakuwa, T., S. Endo, H. Nakae, M. Kikuchi, N. Baba, K. Inada, and M. Yoshida. 1994. Blood cytokine and complement levels in patients with sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84: 291-300.
34. Fearon, D. T., S. Ruddy, P. H. Schur, and W. R. McCabe. 1975. Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N. Engl. J. Med. 292: 937-940.
35. León, C., M. J. Rodrigo, A. Tomasa, M. T. Gallart, F. J. Latorre, J. Rius, and J. Brugués. 1982. Complement activation in septic shock due to gram-negative and gram-positive bacteria. Crit. Care Med. 10: 308-310.
36. Friedman, G., S. Jankowski, A. Marchant, M. Goldman, R. J. Kahn, and J. L. Vincent. 1997. Blood interleukin 10 levels parallel the severity of septic shock. J. Crit. Care 12: 183-187.
37. Ward, P. A., and H. Gao. 2009. Sepsis, complement and the dysregulated inflammatory response. J. Cell. Mol. Med. 13: 4154-4160.
38. Pfeifer, P. H., M. S. Kawahara, and T. E. Hugli. 1999. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin. Chem. 45: 1190-1199.
39. Basta, M., F. Van Goor, S. Luccioli, E. M. Billings, A. O. Vortmeyer, L. Baranyi, J. Szebeni, C. R. Alving, M. C. Carroll, I. Berkower, et al. 2003. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat. Med. 9: 431-438.
40. Huber-Lang, M., J. V. Sarma, D. Rittirsch, H. Schreiber, M. Weiss, M. Flierl, E. Younkin, M. Schneider, H. Suger-Wiedeck, F. Gebhard, et al. 2005. Changes in the novel orphan, C5a receptor (C5L2), during experimental sepsis and sepsis in humans. J. Immunol. 174: 1104-1110.
41. Cain, S. A., and P. N. Monk. 2002. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 277: 7165-7169.
42. Bamberg, C. E., C. R. Mackay, H. Lee, D. Zahra, J. Jackson, Y. S. Lim, P. L. Whitfeld, S. Craig, E. Corsini, B. Lu, et al. 2010. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol. Chem. 285: 7633-7644.
43. Naik, N., E. Giannini, L. Brouchon, and F. Boulay. 1997. Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J. Cell Sci. 110: 2381-2390.
44. Boulay, F., and M. J. Rabiet. 2005. The chemoattractant receptors FPR and C5aR: same functions - different fates. Traffic 6: 83-86.
45. Suvorova, E. S., J. M. Gripentrog, and H. M. Miettinen. 2005. Different endocytosis pathways of the C5a receptor and the N-formyl peptide receptor. Traffic 6: 100-115.
46. Kalkoff, M., R. T. Cursons, J. W. Sleigh, and G. M. Jacobson. 2004. The use of real time rtPCR to quantify inflammatory mediator expression in leukocytes from patients with severe sepsis. Anaesth. Intensive Care 32: 746-755.
47. Müller, B., G. Peri, A. Doni, A. P. Perruchoud, R. Landmann, F. Pasqualini, and A. Mantovani. 2002. High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J. Leukoc. Biol. 72: 643-649.
48. Penton-Rol, G., S. Orlando, N. Polentarutti, S. Bernasconi, M. Muzio, M. Introna, and A. Mantovani. 1999. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J. Immunol. 162: 2931-2938.
49. Van Zee, K. J., T. Kohno, E. Fischer, C. S. Rock, L. L. Moldawer, and S. F. Lowry. 1992. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. USA 89: 4845-4849.
50. Schneider, E. M., S. Flacke, F. Liu, M. R. Lorenz, P. Schilling, M. E. Nass, K. J. Foehr, M. Huber-Lang, and M. E. Weiss. 2011. Autophagy and ATP-induced anti-apoptosis in antigen presenting cells (APC) follows the cytokine storm in patients after major trauma. J Cell Commun Signal 5: 145-156.
51. Nusbaum, P., C. Lainé, M. Bouaouina, S. Seveau, E. M. Cramer, J. M. Masse, P. Lesavre, and L. Halbwachs-Mecarelli. 2005. Distinct signaling pathways are involved in leukosialin (CD43) down-regulation, membrane blebbing, and phospholipid scrambling during neutrophil apoptosis. J. Biol. Chem. 280: 5843-5853.
52. Guo, R. F., L. Sun, H. Gao, K. X. Shi, D. Rittirsch, V. J. Sarma, F. S. Zetoune, and P. A. Ward. 2006. In vivo regulation of neutrophil apoptosis by C5a during sepsis. J. Leukoc. Biol. 80: 1575-1583.
53. Mortensen, R. F. 2001. C-reactive protein, inflammation, and innate immunity. Immunol. Res. 24: 163-176.
54. Mortensen, R. F., and W. Zhong. 2000. Regulation of phagocytic leukocyte activities by C-reactive protein. J. Leukoc. Biol. 67: 495-500.
55. Heuertz, R. M., G. P. Schneider, L. A. Potempa, and R. O. Webster. 2005. Native and modified C-reactive protein bind different receptors on human neutrophils. Int. J. Biochem. Cell Biol. 37: 320-335.
56. Lobo, S. M., F. R. Lobo, D. P. Bota, F. Lopes-Ferreira, H. M. Soliman, C. Mélot, and J. L. Vincent. 2003. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 123: 2043-2049.
57. Wolbink, G. J., A. W. Bossink, A. B. Groeneveld, M. C. de Groot, L. G. Thijs, and C. E. Hack. 1998. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J. Infect. Dis. 177: 81-87.
58. Szalai, A. J., F. W. van Ginkel, Y. Wang, J. R. McGhee, and J. E. Volanakis. 2000. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J. Immunol. 165: 1030-1035.
59. Jones, S. A., D. Novick, S. Horiuchi, N. Yamamoto, A. J. Szalai, and G. M. Fuller. 1999. C-reactive protein: a physiological activator of interleukin 6 receptor shedding. J. Exp. Med. 189: 599-604.
60. Furebring, M., L. Håkansson, P. Venge, and J. Sjölin. 2004. Differential expression of the C5a receptor and complement receptors 1 and 3 after LPS stimulation of neutrophils and monocytes. Scand. J. Immunol. 60: 494-499.
61. Hawlisch, H., Y. Belkaid, R. Baelder, D. Hildeman, C. Gerard, and J. Köhl. 2005. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22: 415-426.